Exosomes Released From U87 Glioma Cells Treated With Curcumin And/Or Temozolomide Produce Apoptosis in Naive U87 Cells Publisher Pubmed



Mousavi SM¹ ; Hosseindoost S² ; Mahdian SMA³ ; Vousooghi N^{4, 5} ; Rajabi A⁶ ; Jafari A^{7, 8} ; Ostadian A⁸ ; Hamblin MR⁹ ; Hadjighassem M^{1, 10} ; Mirzaei H¹¹
Source: Pathology Research and Practice Published:2023

Abstract

Glioblastoma (GBM) remains the most lethal brain tumor without any curative treatment. Exosomes can mediate cell-to-cell communication, and may function as a new type of targeted therapy. In this study, the therapeutic benefits of exosomes generated by U87 cells treated with curcumin and/or temozolomide were investigated. The cells were cultured and treated with temozolomide (TMZ), curcumin (Cur), or their combination (TMZ+Cur). Exosomes were isolated with a centrifugation kit and characterized using DLS, SEM, TEM, and Western blotting. The levels of exosomal BDNF and TNF-α were measured. Naive U87 cells were treated with the isolated exosomes, and the effects on apoptosis-related proteins HSP27, HSP70, HSP90, and P53 were assessed. All exosomes, Cur-Exo, TMZ-Exo, and TMZ+Cur-Exo increased cleaved caspase 3, Bax, and P53 proteins, while reducing HSP27, HSP70, HSP90, and Bcl2 proteins. Moreover all treatment groups increased apoptosis in naive U87 recipient cells. Exosomes released from treated U87 cells had less BDNF and more TNF-α compared to exosomes released from naive U87 cells. In conclusion, we showed for the first time that exosomes released from drug-treated U87 cells could be a new therapeutic approach in glioblastoma, and could reduce the side effects produced by drugs alone. This concept needs to be further examined in animal models before clinical trials could be considered. © 2023 Elsevier GmbH